Between 5% and 20% of BP1-BP2 deletions arise de novo. An analysis looking into the UK BioBank (UKBB) cohort confirmed the increased association of CHD with BP1-BP2 deletion (Williams et al., 2020); among patients in UKBB with CHD, the deletion was more frequently present than among controls. This evidence concerns the gene IGFBP2 and coronary artery disorder.